Note 12 - Senior Credit Facility:

($ amounts in thousands)



	June 30, 2012			December 31, 2011
Term Loan Facility	$	336,875		$	345,625
Revolving Credit Facility	—			—
	336,875			345,625
Less current portion	(30,625		)	(21,875		)
Long-term debt	$	306,250		$	323,750

In connection with our acquisition of Anchen, a privately-held specialty pharmaceutical company, we entered into a credit agreement (the "Credit Agreement") with a syndicate of banks, led by JPMorgan Chase Bank, N.A., as Administrative Agent, U.S. Bank National Association and PNC Bank, National Association as Co-Syndication Agents, DnB NOR Bank ASA and SunTrust Bank as Co-Documentation Agents, J.P. Morgan Securities LLC as Sole Bookrunner, and J.P. Morgan Securities LLC, U.S. Bank National Association and PNC Bank Capital Markets LLC as Joint Lead Arrangers, to provide senior credit facilities to be comprised of a five-year Term Loan Facility in an initial aggregate principal amount of $350,000 thousand and a five-year Revolving Credit Facility in an initial amount of $100,000 thousand. We used the proceeds of the Term Loan Facility, together with cash on hand, to finance our acquisition of Anchen, and the proceeds of the Revolving Credit Facility are available for general corporate purposes.

The Credit Agreement contains customary representations and warranties, as well as customary events of default, in certain cases subject to reasonable and customary periods to cure, including but not limited to: failure to make payments when due, breach of covenants, breach of representations and warranties, insolvency proceedings, certain judgments and attachments and any change of control. The Credit Agreement also contains various customary covenants that, in certain instances, restrict our ability to: (i) incur additional indebtedness; (ii) create liens on assets; (iii) engage in acquisitions of other companies, products or product lines or mergers or consolidations; (iv) engage in dispositions of assets; (v) make investments, loans, guarantees or advances in or to other companies; (vi) pay dividends and distributions or repurchase capital stock; (vii) enter into sale and leaseback transactions; (viii) engage in transactions with affiliates; and (ix) change the nature of our business. In addition, the Credit Agreement requires us to maintain the following financial covenants: (a) a maximum leverage ratio, and (b) a minimum fixed charge coverage ratio. While initially unsecured, we could be obligated to secure our obligations under the Credit Agreement should our leverage ratio exceed a predetermined threshold for two consecutive quarters. We were in compliance with all financial covenants as of June 30, 2012. All obligations under the Credit Agreement are guaranteed by our material domestic subsidiaries, including Par Pharmaceutical, Inc., Anchen Incorporated, and Anchen Pharmaceuticals, Inc.

The interest rates payable under the Credit Agreement is based on defined published rates plus an applicable margin. During the six months ended June 30, 2012, the effective interest rate on the five-year Term Loan Facility was approximately 2.8%. We are obligated to pay a commitment fee based on the unused portion of the Revolving Credit Facility. The Credit Agreement includes an accordion feature pursuant to which we are able to increase the amount available to be borrowed by up to an additional $150,000 thousand under certain circumstances. Repayments of the proceeds of the Term Loan Facility are due in quarterly installments over the term of the Credit Agreement. Amounts borrowed under the Revolving Credit Facility would be payable in full upon expiration of the Agreement. The Credit Agreement expires in five years. Based on the variable interest rate associated with the Term Loan Facility, its carrying value approximated its fair value at June 30, 2012.



Debt Maturities as of June 30, 2012	($ amounts in thousands)
2012	$	13,125
2013	39,375
2014	56,875
2015	96,250
2016	131,250
Total debt at June 30, 2012	$	336,875